HAYWARD,
Calif., March 21, 2023 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that it will release full year
and fourth quarter financial results for 2022 after the market
close on Thursday, March 30, 2023. Thereafter, AcelRx
management will host a live webcast and conference call
at 4:30 p.m. Eastern Daylight Time/1:30
p.m. Pacific Daylight Time on March 30, 2023 to
discuss the financial results and provide an update on the
Company's business.
Webcast Information
The webcast can be accessed
here or by visiting the "Investors" section of the Company's
website at www.acelrx.com and clicking on the webcast
link within the News & Events/Upcoming Events section. The
webcast will include a slide presentation and a replay will be
available on the AcelRx website for 90 days following the
event.
Conference Call Information
Investors who wish to
participate in the conference call may do so by dialing
1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian
callers, 1-412-902-4204 (toll applies) for international callers.
The conference ID is 10175958.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S.,
DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as
DZUVEO® in Europe, indicated for the management of
acute pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include:
Zalviso® (sufentanil sublingual tablet system, SST
system, 15 mcg), an investigational product in
the U.S. being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings; two
pre-filled, ready-to-use syringes of ephedrine and phenylephrine
licensed for the U.S. from Aguettant. AcelRx's lead
nafamostat program is Niyad™, a regional anticoagulant for the
extracorporeal circuit, and it is also developing LTX-608, for the
potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. AcelRx plans to submit an Emergency Use Authorization
(EUA) to the U.S. Food and Drug Administration (FDA) for Niyad,
which has Breakthrough device designation status, during the second
quarter of 2023. AcelRx also is developing two pre-filled,
ready-to-use syringes (PFS-01 and PFS-02) of ephedrine and
phenylephrine, respectively, licensed for the U.S. from
Aguettant. AcelRx plans to file an NDA on PFS-01 also by the end of
the second quarter of 2023. This release is intended for investors
only. For additional information about AcelRx, please
visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-full-year-and-fourth-quarter-2022-financial-results-call-and-webcast-on-march-30-2023-301777828.html
SOURCE AcelRx Pharmaceuticals, Inc.
